Suppr超能文献

制定效价测定的规范——基本原则

Setting specifications for potency assays--basic principles.

作者信息

Mire-Sluis A R

机构信息

CancerVax Corporation, Carlsbad, CA 92008, USA.

出版信息

Dev Biol (Basel). 2002;107:107-15.

Abstract

To develop any biological therapeutic successfully, it is necessary to characterise the product thoroughly, both physicochemically and biologically. To ensure that consistency of production is maintained, some level of control is required to limit the variability of the product from batch to batch. This premise forms the basis of specification setting. The biological activity or potency of the product must be appropriately assessed through a functional assay unless specifically justified otherwise e.g. for binding proteins where binding has been correlated with biological activity. Biological assays are particularly prone to assay variability and therefore it is necessary to design and execute the assay to reduce variability as much as possible while providing a statistically valid measure of the reproducibility of potency estimates. Therefore, specifications for potency should only be derived following establishment of a well validated and controlled bioassay and should include some measure of the variability of the estimate in addition to the actual potency estimate itself. The limits applied to those specifications need to reflect the true batch to batch consistency of the product, its nature and toxicity as well as its intended use.

摘要

要成功开发任何生物疗法,有必要从物理化学和生物学两方面对产品进行全面表征。为确保生产的一致性得以维持,需要一定程度的控制来限制批次间产品的变异性。这一前提构成了规格设定的基础。除非另有特别合理的理由,例如对于结合蛋白而言结合已与生物活性相关联,否则产品的生物活性或效力必须通过功能测定进行适当评估。生物测定特别容易出现测定变异性,因此有必要设计并执行测定,以尽可能减少变异性,同时提供效力估计值再现性的统计有效度量。因此,效力规格应仅在建立了充分验证和控制的生物测定之后得出,并且除了实际效力估计值本身之外,还应包括对估计变异性的某种度量。应用于这些规格的限度需要反映产品真正的批次间一致性、其性质和毒性以及其预期用途。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验